Login to Your Account


Vertex widens CF net: FDA approves Orkambi for largest patient subset

By Jennifer Boggs
Managing Editor

Thursday, July 2, 2015

Vertex Pharmaceuticals Inc.'s Orkambi won FDA approval Thursday, as largely expected, expanding the firm's reach into the cystic fibrosis (CF) market and serving as a "great example of what precision medicine can do and will do in the future," said Chairman, President and CEO Jeff Leiden.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription